Although the roles of upregulation of CHK in the development of breast tumors is unknown, the mechanism that trastuzumab induces CHK mediated ErbB2 degradation, leading to the inhibition of breast cancer cell growth may be used as a novel strategy to treat ErbB2-positive breast cancers (Dokmanovic et al., 2014). The gene discussed is ERBB2; the disease is breast neoplasm.